ADHERIUM ORD
Adherium Surpasses CY2025 Shipment Milestones, Bolstering RPM Growth Strategy
Adherium (ADR.ASX) has announced it has surpassed its calendar year **2025** device shipment targets, delivering **4,666** devices against a goal of **4,000**, including **2,034** RPM devices against
Market wrap: Australian market follows Wall Street down
Once again, an Australian encore followed a Wall Street sell-off as investors grew increasingly nervous about the prospect for rate falls, with bond yields rising and shares in interest rate sensitive areas falling. Weakness in commodity prices didn’t help the Australian market, with falling prices for iron ore and gold helping to broaden the decline […]
Adherium partners with AstraZeneca for Hailie Smartinhaler clinical trial
Digital health solutions specialist Adherium (ASX: ADR) is celebrating news that global biopharmaceutical giant AstraZeneca has selected its Hailie Smartinhaler platform for a clinical trial. Under the contract, valued at $1.1 million, AstraZeneca will use the devices to record and transfer medication usage data over a period of three years. Adherium will provide Hailie Smartinhalers, […]
Adherium’s Hailie Smartinhaler receives FDA approval for use with leading AstraZeneca devices
Medical device developer Adherium (ASX: ADR) has been given clearance by the US Food and Drug Administration (FDA) for its Hailie Smartinhaler to be used with AstraZeneca’s Airsupra and Breztri inhalation devices. Airsupra is the first FDA-approved rescue medication for asthma patients and Breztri is a triple combination for patients with chronic obstructive pulmonary disorder […]
